期刊文献+

慢性髓系白血病患者体内尼洛替尼血药浓度测定方法建立与应用 被引量:2

Establishment and Application of a Method for Determining Nilotinib Concentration in Patients with Chronic Myeloid Leukemia
下载PDF
导出
摘要 目的:采用高效液相色谱-串联质谱法(HPLC-MS/MS)建立测定人血浆中尼洛替尼浓度的检测方法。方法:血样经甲醇除蛋白后,流动相分别为0.1%甲酸的甲酸铵缓冲液(A相)和0.1%甲酸的乙腈溶液(B相)梯度洗脱,LunaC_(18)柱(20 mm×2.0 mm,3μm)色谱柱分离,流速为0.6 ml·min^(-1);柱温35℃;电喷雾离子源(ESI),正离子模式,多反应监测,离子对为m/z 530.1→m/z 288.9(尼洛替尼)、m/z 502.3→m/z 394.1(伊马替尼-D8)。结果:尼洛替尼的线性范围为50~10000 ng·ml^(-1),定量下限为50 ng·ml^(-1);日内及日间RSD均小于10%,尼洛替尼低、中、高浓度的提取回收率分别为98.5%,102.4%,103.3%。结论:本检测方法操作简单、灵敏度高、检测下限低、专属性强,适用于临床慢性髓系白血病(CML)患者血浆中尼洛替尼的检测。 Objective:To establish a method for the determination of nilotinib in human plasma by HPLC-MS/MS.Methods:Plasma samples were precipitated by methanol.High performance liquid chromatographic separation was performed on a LunaC_(18) column(20 mm×2.0 mm,3μm)with 0.1%formic acid in both ammonium formate buffer solution and acetonitrile as the mobile phase in a gradient elution manner.The flow rate was 0.6 ml·min-1 and the column temperature was 35℃.Electrospray ionization(ESI)with a positive-ion and multiple reactions monitoring mode was adopted.The ion pairs were m/z 503.1→m/z 288.9 for nilotinib,and m/z 502.3→m/z 394.1 for imatinib-D8.Results:The linear range of nilotinib was 50-10000 ng·ml^(-1),and the lower limit of quantitation was 50 ng·ml^(-1);the intra-and inter-day relative standard deviations were lower than 10%.The extraction recoveries of low,medium and high concentration control samples were 98.5%,102.4%and 103.3%,respectively.Conclusion:The method has the advantages of simplicity,high sensitivity,low detection limit and strong specificity.It is suitable for the determination of nilotinib in chronic myeloid leukemia(CML)patients.
作者 程芳 李强 王静林 曾芳 黎纬明 张玉 Cheng Fang;Li Qiang;Wang Jinglin;Zeng Fang;Li Weiming;Zhang Yu(Department of Pharmacy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Hubei Province Clinical Research Center for Precision Medicine for Critical Illness;Department of Hematology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology)
出处 《中国药师》 CAS 2022年第8期1379-1383,共5页 China Pharmacist
基金 湖北省重点研发计划项目(编号:2020BCA060)。
关键词 尼洛替尼 血药浓度 高效液相色谱串联质谱 慢性髓系白血病 Nilotinib Concentration in human plasma HPLC-MS/MS Chronic myeloid leukemia
  • 相关文献

参考文献9

二级参考文献59

  • 1王楚慧,刘洋,赵思璇,张弨.万古霉素群体药代动力学模型系统研究[J].中国临床药理学杂志,2020,36(3):354-356. 被引量:6
  • 2邹丽萍.儿童抗癫痫药物的合理应用[J].临床药物治疗杂志,2004,2(6):16-20. 被引量:6
  • 3翁静艳,杭太俊,顾洁,吴晓鸾,甘春,杨林,文爱东.液相色谱-串联质谱法测定辛伐他汀片的人体药动学和生物等效性[J].中国新药与临床杂志,2007,26(5):347-351. 被引量:10
  • 4Blay JY,von Mehren M.Nilotinib:a novel,selective tyrosine kinase inhibitor[J].Semin Oncol,2011,38 (Suppl 1):S3-9. 被引量:1
  • 5Fullmer A,Kantarjian H,Cortes J,et al.Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia[J].Expert Opin Pharmacother,2010,11 (18):3065-3072. 被引量:1
  • 6Breccia M,Alimena G.Nilotinib:a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia[J].Leuk Res,2010,34(2):129-134. 被引量:1
  • 7Giles FJ,Rosti G,Beris P,et al.Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia:the ENESTnd study[J].Expert Rev Hematol,2010,3(6):665-673. 被引量:1
  • 8Davies A,Hayes AK,Knight K,et al.Simultaneous determination of nilotinib,imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography[J].Leuk Res,2010,34(6):702-707. 被引量:1
  • 9Miura M,Takahashi N,Sawada K.High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma[J].Biomed Chromatogr.2010,24(7):789-793. 被引量:1
  • 10De Francia S,D'Avolio A,De Martino F,et al.New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib,dasatinib,and nilotinib in human plasma[J].J Chromatogr B Analyt Technol Biomed Life Sci,2009,877(18-19):1721-1726. 被引量:1

共引文献31

同被引文献6

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部